VoxCell and Partners Enhance Radiation Therapy with Vascularized 3D Tissue Models

Victoria, May 2025—VoxCell BioInnovation announced a strategic collaboration with the University of Victoria and BC Cancer, combining nanotechnology, radiation therapy, and 3D bioprinted vascularized tumour models.

Launching this month, this project will explore the application of VoxCell’s vascularized triple-negative breast cancer tissue models as a human-relevant platform for radiation-enhancing nanotherapies.

partnership overview

This collaboration combines interdisciplinary expertise to evaluate novel nanoparticle-based approaches for improving cancer radiotherapy. Specifically:

• Radiation-enhancing nanoparticles developed by Dr. Alexandre Brolo’s lab at the University of Victoria will be perfused through VoxCell’s bioprinted vascularized breast cancer models, mimicking real human tissue delivery.

• BC Cancer’s clinical-grade radiation facilities, in partnership with Dr. Julian Lum, will be used to irradiate the tissues under controlled therapeutic conditions.

• Post-treatment analysis will be conducted collaboratively by VoxCell and University of Victoria researchers to assess therapeutic impact and biological response.

The Role of Vascularized Models in Radiation and Nanotherapy Research

By integrating advanced nanotechnology with VoxCell’s biomimetic vascular networks, this project will generate insights that are difficult to obtain from traditional in vitro models. The goal is to create more predictive tools for cancer therapy testing, particularly in the context of radiation-enhanced nanotherapeutics.

About VoxCell BioInnovation

VoxCell BioInnovation is a leading provider of next-generation in vitro models, powered by our 3D bioprinted, vascularized tissue technology. Our ready-to-perfuse models closely replicate human biology with in vivo–like microvascular networks, enabling nutrient and oxygen delivery, systemic drug distribution, and more predictive therapeutic responses. VoxCell’s end-to-end solution offers researchers and pharmaceutical companies a scalable, ethical alternative to animal testing. Our mission is to reduce reliance on animal models, accelerate preclinical development, and advance more effective therapies for patients.

Want to learn more or collaborate?

Visit our website, connect with us on LinkedIn, or email us at hello@voxcellbio.com.